Approval · Notice of Compliance 27503 · 2022
AGRYLIN: Notice of Compliance 27503
Issued January 31, 2022
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 27503
- Date
- January 31, 2022
- Company
- Takeda Canada IncorporatedToronto, Ontario, Canada
- Product type
- Prescription Pharmaceutical
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Safety updates to the Product Monograph
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| AGRYLIN | Not yet assigned | — |
Medicinal ingredients
- ANAGRELIDE HYDROCHLORIDE 0.5 MG per CAP